Nemtabrutinib and Pembrolizumab in Patients With Richter Transformation: A Phase II Study
Latest Information Update: 13 Mar 2025
At a glance
- Drugs Nemtabrutinib (Primary) ; Pembrolizumab (Primary)
- Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Hepatitis B; Hepatitis C; Richter's syndrome
- Focus Therapeutic Use
Most Recent Events
- 11 Mar 2025 New trial record
- 10 Mar 2025 Planned initiation date changed from 1 Apr 2025 to 1 Jul 2025.